Shares of Krystal Biotech Inc. (KRYS) have now more than doubled in value since touching a 52-week low of $22.02 on June 14, 2019.
Krystal Biotech is a clinical-stage gene therapy company developing topical and intradermal novel treatments for patients suffering from rare dermatological diseases and chronic skin diseases.
We had profiled this Company on June 8, 2018, when it was trading around $12.72 (Report titled In The Spotlight: Krystal Biotech) and had alerted readers to this stock again on December 4, 2018, when it was trading around $24. (Report titled Krystal Is Clearer, Hits New High). The stock now trades around $54.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.